Sabitar 24 mg+26 mg (Tablet)
Unit Price: ৳ 45.00 (3 x 10: ৳ 1,350.00)
Strip Price: ৳ 450.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sacubitril valsartan |
| Company | Incepta pharmaceuticals ltd |
| Also available as |
Indications
- Reduces cardiovascular death risk
- Reduces hospitalization risk for heart failure
- For chronic heart failure (NYHA Class ll-IV)
- For symptomatic heart failure in pediatric patients (aged one year and older)
- Administered in conjunction with other heart failure therapies
- Usable in place of an angiotensin-converting enzyme inhibitor (ACEi) or other ARB
Pharmacology
- Contains neprilysin inhibitor (sacubitril) and angiotensin receptor blocker (valsartan)
- Inhibits neprilysin (neutral endopeptidase) via LBQ657
- Blocks angiotensin II type-1 (AT1) receptor via valsartan
- Increases levels of peptides degraded by neprilysin
- Simultaneously inhibits effects of angiotensin II by valsartan
Dosage & Administration
- Recommended starting dose for adult heart failure: 49/51 mg orally twice daily
- Target maintenance dose for adult heart failure: 97/103 mg twice daily
- Pediatric patients aged one year and older have different dose recommendations
- Dosage adjustment for patients with severe renal impairment
- Dosage titration based on pediatric patient weight
Interaction
- Should not be used with ACEi, aliskiren in patients with diabetes
- Use with ARB should be avoided
- Potassium-sparing diuretics may increase serum potassium level
- NSAIDs may increase risk of renal impairment
- Increased risk of lithium toxicity when used with lithium
Contraindications
- Hypersensitivity to any component
- History of angioedema related to previous ACE inhibitor or ARB therapy
- Concomitant use of ACE inhibitors or aliskiren in patients with diabetes
Side Effects
- Angioedema
- Hypotension
- Impaired renal function
- Hyperkalemia
- Cough
- Dizziness
Pregnancy & Lactation
- Safety and effectiveness not established in pediatric patients less than 1 year of age
- No relevant pharmacokinetic differences observed in elderly patients
- No dose adjustment required for mild hepatic impairment
- Not recommended in patients with severe hepatic impairment
- No dose adjustment required in patients with mild to moderate renal impairment
- Recommended starting dose for patients with severe renal impairment
Precautions & Warnings
- May cause angioedema
- May lower blood pressure and cause symptomatic hypotension
- Monitor serum creatinine
- Monitor serum potassium periodically and treat appropriately
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
- No relevant pharmacokinetic differences observed in elderly patients
- Different starting dose recommendations for patients with renal or hepatic impairment
Overdose Effects
- Hypotension likely result of overdosage
- Symptomatic treatment should be provided
Storage Conditions
- Keep in a dry place
- Store below 30°C
- Protect from moisture
- Keep out of the reach of children